The H-Share Market Will Soon Be Reported To Huarun By &Nbsp, Which Means There Are Three Major Problems.

According to Hong Kong media reports, Shanghai Pharmaceutical (20.06,0.20,1.01%) (2607) Prospectus has already been completed, but suddenly appeared in Anhui, a drug distribution peer, to the HKEx and

According to Hongkong media reports, the Shanghai Pharmaceutical (2607) Prospectus has already been completed and investors are waiting for Friday.

According to a copy of the letter of complaint received by the media, the letter was issued by the Huayuan Pharmaceutical Limited by Share Ltd of Anhui, and the company seal was made and the addressee was the HKEx and the SFC.

There are a total of three complaints, mainly around the dispute between Anhui Huayuan and Shanghai new pioneers and the two companies of Hua Kang medicine.

Its company was frozen.

According to the drug prospectus, the new pioneer of Shanghai is wholly owned by the pharmaceutical company of Shanghai pharmaceutical parent company. Now it is entrusted by the parent company to manage the listed company.

As for Hua Kang, which is wholly owned by the parent company, it has been arranged for acquisition by the listed company. The paction is expected to be completed by the end of June this year.

The report pointed out that the new pioneer and a pharmaceutical produced by Hua Kang claimed that the raw materials came from Japan. However, it has not been able to provide relevant documents. "There is reason to suspect that the raw materials are disguised as Japanese imports."

At the same time, the product was repeatedly complained of serious quality problems. Finally, as a distributor of Anhui, Huayuan, the chief distributor of the product, filed a lawsuit with the Anhui court because of its failure to negotiate with the new pioneer and hukang, and last month ordered the freezing of property and bank accounts of 39 million 560 thousand yuan.

In search of information, Anhui Huayuan, a drug with a name complaint, is the Affiliated Companies of Huarun group Beijing medical group of Huarun group, which mainly deals in wholesale and distribution of pharmaceutical products.

Li Li, a legal consultant in Anhui Huayuan yesterday, admitted that the letter was sent by the company. At the same time, he confirmed that Anhui Huayuan was an enterprise of Huarun group.

The response index has nothing to do with the listed company.

Han Min, Secretary of the board of directors, said that there was no comment on the quality of drugs and the freezing of property, but that they had not received any documents referred to by the HKEx. However, she said that he had already known the complaints of Anhui Huayuan, and that "those who had disputes with them (referred to as new pioneers and Wah Kang") were not listed in the listed companies, and had nothing to do with the listed companies.

And the lawsuit had already appeared before the company was commissioned.

Han Min stressed that disputes will not affect the listing of drugs.

According to the news of the underwriting group, at the same time, the drugs listed on the A share market had been handed over to mainland regulators by the mainland authorities earlier, and the section "relationship with the controlling shareholders" in the H share prospectus has also been disclosed.

A spokesman for the Hong Kong Stock Exchange yesterday said that it would never confirm or comment on individual incidents. If any letter was received, it would decide the next move depending on the content.

The spokesman pointed out that the relevant listed companies will publish announcements or supplement the listing documents at that time.